Format

Send to

Choose Destination
Nat Rev Immunol. 2009 Oct;9(10):704-16. doi: 10.1038/nri2635.

Engineering lymphocyte subsets: tools, trials and tribulations.

Author information

1
Department of Pathology and Laboratory Medicine and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA. cjune@exchange.upenn.edu

Abstract

Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.

PMID:
19859065
PMCID:
PMC3412112
DOI:
10.1038/nri2635
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Grant support

Publication types

MeSH terms

Grant support

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center